bluebird bio Inc

Latest Results (06.11.2025):

bluebird bio Inc's third quarter 2024 financial report highlights a mixed performance with lower net revenue relative to the previous year but improved expense management and a narrower net loss. The company reported key metrics for the quarter, including revenue, costs, and cash position, along with forward-looking guidance regarding increasing patient starts and the potential to achieve cash flow break-even in the second half of 2025.

Revenue Performance

For Q3 2024, bluebird bio Inc reported total net revenue of $10.6 million, down from $12.3 million in Q3 2023, reflecting variability in drug product infusions. The company anticipates a significant rebound in Q4 2024 with expected net revenue of at least $25 million, as previously reported patient starts begin to infuse.

Expense Management and Net Loss

The cost of product revenue increased to $11.8 million compared to $9.1 million in the prior year period. SG&A expenses were slightly lower at $39.8 million versus $40.8 million, and R&D expenses saw a notable decrease to $23.2 million from $58.5 million. These factors helped reduce the net loss to $60.8 million in Q3 2024 from $87.2 million in Q3 2023.

Cash Position and Future Outlook

As of September 30, 2024, bluebird bio Inc’s cash, cash equivalents, and restricted cash totaled approximately $118.7 million, with a restricted amount of about $48.0 million. The company projects that its current cash will support operations into the first quarter of 2025, and with planned cost-saving initiatives and additional financing, it aims for quarterly cash flow break-even in the second half of 2025.

Commercial Launch Updates

bluebird bio Inc reported 74 patient starts in 2024 across its commercial portfolio, with continued momentum evident from a doubling in patient starts from the second to the third quarter. With 57 patient starts completed and additional starts scheduled through 2024, the robust commercial demand is further supported by established access strategies and favorable reimbursement from states.